SCHEMBL14231500

SCHEMBL14231500

CN[C@H]1C[C@@H](n2c3ccccc3c3c4c(c5c6ccccc6[nH]c5c32)CNC4=O)O[C@H](C)[C@H]1OC

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 11/20 0.70
PRKCQ Q04759 8/20 0.70
KDR P35968 6/20 0.69
MAP3K5 Q99683 5/20 0.69
JAK2 O60674 3/20 0.69
ABL1 P00519 3/20 0.69
ERBB2 P04626 3/20 0.69
LCK P06239 3/20 0.69
LYN P07948 3/20 0.69
RET P07949 3/20 0.69
PDGFRB P09619 3/20 0.69
KIT P10721 3/20 0.69
FGFR1 P11362 3/20 0.69
CDK4 P11802 3/20 0.69
SRC P12931 3/20 0.69
FGFR3 P22607 3/20 0.69
CCND1 P24385 3/20 0.69
CCNE1 P24864 3/20 0.69
CDK2 P24941 3/20 0.69
FLT3 P36888 3/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20609293 0.83 PRKCQ (0.65) ROCK2PRKCQKDRMAP3K5JAK2
SCHEMBL12570349 0.82 PRKCQ (0.85) ROCK2PRKCQKDRMAP3K5PRKCA
SCHEMBL12570608 0.82 PRKCQ (0.85) ROCK2PRKCQKDRMAP3K5PRKCA
SCHEMBL12570606 0.82 PRKCQ (0.85) ROCK2PRKCQKDRMAP3K5PRKCA
SCHEMBL24606232 0.82 PRKCZ (1.00) ROCK2PRKCQKDRMAP3K5JAK2
SCHEMBL18808417 0.82 PRKCZ (1.00) ROCK2PRKCQKDRMAP3K5JAK2
SCHEMBL20333841 0.82 PRKCZ (1.00) ROCK2PRKCQKDRMAP3K5JAK2
SCHEMBL14845612 0.82 PRKCZ (1.00) ROCK2PRKCQKDRMAP3K5JAK2
SCHEMBL19050325 0.81 PRKCQ (0.75) ROCK2PRKCQKDRMAP3K5PRKCA
SCHEMBL30885079 0.81 PRKCQ (1.00) ROCK2PRKCQKDRMAP3K5PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080081078-A1 Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081078-A1 Prevention of Cell Proliferation by Inhibiting Myosin Light Chain Kinase MYLK3, MYLK, MYLK4 ROCK2 50/4885PRKCQ 379/4885KDR 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.